HSIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Henry Schein Inc (HSIC) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has stable financial growth and a strong position in the dental market, the stock lacks significant positive catalysts, and the current price trend does not indicate a compelling entry point. The SwingMax signal from earlier in April has already seen a 4.21% price change, suggesting the opportunity may have passed. Additionally, the lack of recent news or influential trading activity further supports a hold recommendation.
The technical indicators show a mixed picture. The MACD is positive but contracting, and the RSI is neutral at 71.179. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), suggesting an upward trend. However, the price is close to resistance levels (R1: 77.601, R2: 79.194), limiting immediate upside potential.
Stable financial growth with revenue up 7.71% YoY and EPS up 13.33% YoY in Q4
Citi's buy rating with a $100 price target highlights long-term potential.
SwingMax signal from 2026-04-02 showed a 4.21% price increase since then.
Lack of recent news or event-driven catalysts.
Analyst sentiment is mixed, with some firms expressing concerns about modest growth in a competitive dental market.
Hedge funds and insiders show neutral trading trends, indicating no strong institutional or insider conviction.
In Q4 2025, Henry Schein reported strong financials: Revenue increased by 7.71% YoY to $3.44 billion, Net Income increased by 7.45% YoY to $101 million, and EPS rose by 13.33% YoY to $0.85. However, the gross margin slightly declined to 28.92%, down 0.75% YoY.
Analyst ratings are mixed. Citi initiated a buy rating with a $100 price target, citing optimism in the animal health and dental sectors. However, BTIG rated the stock Neutral, citing modest growth in a competitive market. Several firms raised price targets post-Q4 results, with targets ranging from $84 to $104.
